Advanced Phase I/II Studies of Targeted Gene Delivery In Vivo: Intravenous Rexin-G for Gemcitabine-resistant Metastatic Pancreatic Cancer
Authors:
Open Access
- 1 February 2010
- journal article
- research article
- Published by Elsevier in Molecular Therapy
- Vol. 18 (2) , 435-441
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Phase I/II and Phase II Studies of Targeted Gene Delivery In Vivo: Intravenous Rexin-G for Chemotherapy-resistant Sarcoma and OsteosarcomaMolecular Therapy, 2009
- Biological Approaches to Therapy of Pancreatic CancerPancreatology, 2008
- Phase I Trial of a Pathotropic Retroviral Vector Expressing a Cytocidal Cyclin G1 Construct (Rexin-G) in Patients With Advanced Pancreatic CancerMolecular Therapy, 2008
- Metastatic Pancreatic Cancer: Emerging Strategies in Chemotherapy and Palliative CareThe Oncologist, 2003
- Cancer gene and oncolytic virus therapySeminars in Oncology, 2001
- Supplemental Guidance on Testing for Replication-Competent Retrovirus in Retroviral Vector-Based Gene Therapy Products and During Follow-up of Patients in Clinical Trials Using Retroviral VectorsHuman Gene Therapy, 2001
- Molecular Engineering of Matrix-Targeted Retroviral Vectors Incorporating a Surveillance Function Inherent in von Willebrand FactorHuman Gene Therapy, 2000
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendationsEuropean Journal of Cancer, 1999
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958